Drug Trial Radar · NCT04806854
PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)
Last checked: Nov 19, 2026Latest source record: Oct 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jul 14, 2021
Primary completion
Apr 2030
Study completion Jul 2030
Sponsor
- Lead sponsor
- Lumos PharmaIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 9 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goals of this single site trial are to study the pharmacokinetics (PK) and pharmacodynamics of LUM-201 and effects of LUM-201 administration on growth hormone release over time in children with idiopathic pediatric growth hormone deficiency (PGHD).
Conditions
- Growth Hormone Deficiency
Interventions
LUM-201Drug
Administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of Augmented Growth Hormone (GH) PulsatilityTime frame: Day 1 to Month 6
- Pharmacokinetics of LUM-201 and M8Time frame: Day 1 to Month 6
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of Maternal and Child Research, University of Chile
Santiago, Chile
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.